Posted on January 22, 2008 by Albin Paul
The study published in Jan. 23 issue of the Journal of the American Medical Association is a thumps up for those interested towards personalized medicine, a small but important step.
A person’s genetic make-up seems to influence how he or she reacts to certain hypertension medications. The new study focused on the NPPA (atrial natriuretic precursor A) gene, which is involved in forming atrial natriuretic polypeptide, which acts as a diuretic.
n all, 38,462 people with hypertension underwent genotyping [genetic testing] and were randomly assigned to receive a diuretic (chlorthalidone) or one of the following three drugs: a calcium channel blocker (amlodipine); an angiotensin converting enzyme inhibitor (lisinopril); or an alpha-blocker (doxazosin).
people with hypertension and two different NPPA genotypes (known as NPPA G664A and NPPA T2238C) responded differently to different medications.
Filed under: clinical genomics, genetic medicine, genetics | Leave a comment »
Posted on November 1, 2007 by Albin Paul
Which of the thousands of long stretches of repeated DNA in the human genome came first? And which are the duplicates the question have been answered by a team of scientists from University of Washington School of Medicine and University of California, San Diego.The research published by Evan Eichler from the University of Washington School of Medicine provide the first evolutionary history of the duplications in the human genome that are partly responsible for both disease and recent genetic innovations.
Evan Eichler has analyzed segmental duplications in the human genome and have successfully pinpointed the ancestral origin of each and identified the newly named core duplicon.
The study presents a comprehensive global analysis of the evolution of segmental duplications in the human enome. The authors identify the origin of ancestral duplication loci, regions of clustered duplicons, and evidence upporting a punctuated model of evolution.
This work marks a significant step toward a better understanding of what genomic changes paved the way for modern humans, when these duplications occurred and what the associated costs are – in terms of susceptibility to disease-causing genetic mutations.
Apart from the above study the recently completed (check previous blogs) Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences the study helps to explain the evolutionary origins of human DNA and the role played by transposons
Genomes can duplicate long stretches of DNA from one chromosome and insert the duplication in another area of the genome. The resulting segments of DNA are called segmental duplications. They are important because they hold evolutionary secrets
Finding answers to questions such as, Which set came first? What changes were innovated, when and why? What was sacrificed when an innovation took effect? What is the connection between disease and innovations within segmental duplications?, are important because researchers can then design specific medical treatments and can lead to ket discoveries in Pharmacogenomics research
Download the Research Article
Filed under: bioinformatics, bioinformatics blog, DNA, DNA news, evolution, genetics, genome sequencing, Pharmacogenomics | Leave a comment »
Posted on August 30, 2007 by Albin Paul
Scientists from the Lucile Packard Children’s Hospital and the Stanford University School of Medicine have identified a pattern of gene expression shared by a small group of patients who beat the odds and remained healthy for years without medication, after undergoing Organ transplant.
The findings made by Minnie Sarwal, MD, PhD, a pediatric nephrologist at Packard Children’s is a major advantage in organ transplantation treatment. Transplant recipients who share the same pattern of genes but are still on conventional medication may be able to reduce or eliminate their lifelong dependence on immunosuppressive drugs. The study may also help physicians determine how best to induce acceptance, or tolerance, of donor organs in all transplant patients, regardless of their gene expression profiles.
Although the anti-rejection medications, known as immunosuppressants, tamp down the immune system enough to permit lifesaving organ transplants, their benefits come at a price. They also quash the body’s natural response to dangerous invaders, such as bacteria and viruses, and to rogue cancer cells. Transplant physicians prescribing immunosuppressants to their patients walk a fine line between avoiding organ rejection and increasing the risk of infection and cancer
The researchers used microarray, or gene chip, technology to compare gene expression patterns in blood samples from 16 healthy volunteers with those from three groups of adult kidney transplant recipients from the United States, Canada and France
Filed under: biodefense, bioinformatics blog, cancer, clinical genomics, DNA, DNA diagnostics, gene expression, gene therapy, genetic medicine, genetics, Genomics, microaray blog, Pharmacogenomics, transgenomics | 24 Comments »
Posted on August 27, 2007 by Albin Paul
Well every one is writing about google and its foray into biology and life science, so what is going on with Other companies .
Microsoft started its BioIT alliance During 2006 and guss what Bill Gates said during the launch “Advances in our understanding of the human genome promise to revolutionize medicine and open the door to therapies that are tailored to individuals”, means they have bigger plans. just like google entered 23andME
Founding members of the alliance include Accelrys Software, Affymetrix, Amylin Pharmaceuticals, Applied Biosystems and The Scripps Research Institute, among more than a dozen other life sciences and IT companies.
and the last month Microsoft has released Microsoft Computational Biology Web Tools as open-source some code for analysis of antiviral immunity
Hmm interestingly I found the project details hosted in Codeplex the open source project hosting the details are on at MSCompBio
And then there is Stochastic Pi-Machine the programming language to model and simulate biological systems- a research funded as part of the European Science Initiative
And then there is the webpage at Microsoft research for bioinformatics
But my favourite is this
Towards 2020 Science microsoft
to define and produce a new vision and roadmap of the evolution, challenges and potential of computer science and computing in scientific research in the next fifteen years.
and this beautiful image from the microsft website
Filed under: bioinformatics blog, bioinformatics business, bioinformatics company, DNA, genetics, Genomics, microarray, microarray blog, microsoft | 1 Comment »
Posted on August 23, 2007 by Albin Paul
THe Haifa Lab of IBM provides the Technlogy for Clinicalgenomics and leads the research in lifesciences fieds.
The Clinica, Genomics division plans to provide technology to integrate clinial genomics data and HL7 and other complaince protocls followed in clinical research and clinia, trial and integrate them to provide better and focused clinical trials
Clinical genomics for biopharmaceuticals from IBM
the main advatages as per IBM website is that
- Encapsulate raw genomic data into an HL7 Clinical Genomics message, including transformation services of proprietary data formats to standardized formats like MAGE and BSML
- Access patient’s clinical history stored in an enterprise EHR system
- Access all major ontologies that provide genotype-phenotype relationships like OMIM, PharmGKB, etc.
- Parse the encapsulated raw genomic data and bubble-up selected genomic data items based on ontological knowledge as well as the patient clinical data
- Compare two Genotypes (the data model at the heart of the HL7 specs) in order to provide case-based reasoning services to decision support application that will use CGL7 as a specialized clinical genomics middleware
- Find a similar pedigree in case base of pedigrees in order to support risk assessment applications that base their assessment on family history
Filed under: bioinformatics, clinical genomics, clinical microarray, DNA, DNA diagnostics, gene expression, gene therapy, genetics, microarray blog, Pharmacogenomics, Theranostics | Leave a comment »
Posted on August 20, 2007 by Albin Paul
Ok I did laugh a bit at that story, but interesting ha. according to a study outlined in a report in the Aug. 21 issue of the journal Current Biology Females do have a preference for pinkish colors that males don’t.
So whats the evolutionary reason , well the same old story females used to collect food, the study says Females were the ones who gathered red fruit against a green background,” she said. “Red is healthy in faces and in fruits
so intrigued read on at USNEWS website
Filed under: DNA, DNA in daliy life, genetics, science and entertainment | Leave a comment »
Posted on August 20, 2007 by Albin Paul
interestingly I found this image from an earlier post of Bertalan at scienceroll
The story according to the blog Google Blogoscoped, Google’s nascent Google Health product, codenamed “Weaver”, will offer consumers the opportunity to create a central repository for their health records, including medications, history, test results and allergies. The blog has a number of screenshots of the program in development.
Well google certainly has more up its sleeve, doubt it, chek the google labs page,
Passionate about these topics? You should work at Google. among others listed is interest in genetic algorithms
Filed under: DNA, DNA computer, genetics, Genomics, google, microarray blog, science blog | 5 Comments »